First of all, it is not only my honor to support this management team and lenzilumab, I am also striving to focus on the government's abuse of discretionary authority, and challenge the very existence of Self Regulatory Organizations. I'm a man of simple needs, and feel fortunate, being retired, to be able to dedicate my life to the issues most important to me. Doing what I can to help stop the needless loss of life, and to help make America even greater than it has been in my lifetime, are noble causes, and more than worthy of my time.
This is my second attempt to reply to your post. For my comments to have any value, I have to assess how the company may structure the announcements that I feel certain they will make. What I'm finding most challenging is trying to determine when they will announce regulatory approval of some sort. I know there are rules regarding how long a company can sit on relevant news. But I'm not sure that even applies to us, given where we are.
I have to assume that management will jointly announce with Novavax that a study has been concluded using lenz with their vaccine as prescribed in our patent. Those results are likely before EU regulators, for their consideration and approval. News of partnering with Novavax on this study, and the results of the study, should allow Humanigen to advance in the OTC Market tier to OTCQB, or Venture Market. Pink market would suffice to resume trading.
I think the company may announce that those results were provided to the FDA in a resubmission of our EUA application.
I also think the company will recall their loaned shares. In addition, the company may resume selling shares from their open shelf registration.
Per our list of catalysts, there is additional news to anticipate.
I think that news may be held for our return to Nasdaq.
I would add that management may declare our 5:1 forward split in the next announcement, but I didn't include it because I'm not sure if FINRA has to approve it, or if they even would on the OTC.
It may be a silly scenario, but how do you divide up so much good news between the two uplistings?
